LEONETTI, ALESSANDRO
 Distribuzione geografica
Continente #
EU - Europa 239
NA - Nord America 142
AS - Asia 37
AF - Africa 3
SA - Sud America 1
Totale 422
Nazione #
US - Stati Uniti d'America 138
IT - Italia 99
IE - Irlanda 67
FR - Francia 27
IN - India 13
CN - Cina 10
DE - Germania 7
FI - Finlandia 6
NL - Olanda 6
PL - Polonia 6
CZ - Repubblica Ceca 5
JP - Giappone 5
CA - Canada 3
EG - Egitto 3
PH - Filippine 3
RO - Romania 3
UA - Ucraina 3
VN - Vietnam 3
ES - Italia 2
GB - Regno Unito 2
SE - Svezia 2
TR - Turchia 2
AR - Argentina 1
BE - Belgio 1
GR - Grecia 1
HK - Hong Kong 1
HN - Honduras 1
MK - Macedonia 1
RU - Federazione Russa 1
Totale 422
Città #
Dublin 67
Ashburn 49
Casina 22
Parma 16
Shanghai 10
Boardman 9
Arezzo 7
Boulder 7
Houston 7
Seattle 7
Bremen 6
Gdansk 6
Helsinki 6
Wilmington 6
Chicago 5
Correggio 4
Menlo Park 4
Milan 4
Pisa 4
Pomigliano d'Arco 4
Rome 4
Woodbridge 4
Cairo 3
Naples 3
Pune 3
Vicopisano 3
A Coruña 2
Ahmedabad 2
Ann Arbor 2
Bacoli 2
Bucharest 2
Dong Ket 2
Fairfield 2
Florissant 2
London 2
North Charleston 2
Palermo 2
Richmond 2
San Jose 2
Verona 2
Amsterdam 1
Angeles City 1
Ankara 1
Arlington 1
Bellevue 1
Bologna 1
Cambridge 1
Carlisle 1
Chions 1
Cluj-Napoca 1
Council Bluffs 1
Delhi 1
Faenza 1
Ferrara di Monte Baldo 1
Greve in Chianti 1
Ho Chi Minh City 1
Huddinge 1
Istanbul 1
Jabalpur 1
Kolkata 1
Leominster 1
Louvain-la-Neuve 1
Marano di Napoli 1
Mendoza 1
Mercato San Severino 1
Misano Adriatico 1
Montichiari 1
Mountain View 1
Mumbai 1
Nocera Inferiore 1
Noida 1
Ottawa 1
Pasadena 1
Pontecurone 1
Prilep 1
Rohtak 1
Round Rock 1
Salerno 1
San Mateo 1
St Louis 1
Surrey 1
Troy 1
Urbino 1
Vedelago 1
West Chicago 1
Zográfos 1
Totale 344
Nome #
COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors, file e177fbc7-a3c0-50b0-e053-d805fe0adaee 80
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients, file e177fbc7-1dff-50b0-e053-d805fe0adaee 50
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature, file e177fbc7-aa2c-50b0-e053-d805fe0adaee 41
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors, file e177fbc7-9e55-50b0-e053-d805fe0adaee 29
Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?, file e177fbc7-9fb9-50b0-e053-d805fe0adaee 26
Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?, file e177fbc7-a3b3-50b0-e053-d805fe0adaee 25
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis, file e177fbc7-9f51-50b0-e053-d805fe0adaee 18
A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?, file e177fbc7-a8db-50b0-e053-d805fe0adaee 17
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib, file e177fbc7-a512-50b0-e053-d805fe0adaee 16
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study, file e177fbc7-a397-50b0-e053-d805fe0adaee 15
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy, file e177fbc7-a7c6-50b0-e053-d805fe0adaee 15
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review, file e177fbc7-2761-50b0-e053-d805fe0adaee 14
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?, file e177fbc8-0437-50b0-e053-d805fe0adaee 13
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study, file e177fbc7-a130-50b0-e053-d805fe0adaee 11
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial, file e177fbc7-a01a-50b0-e053-d805fe0adaee 9
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy, file e177fbc7-a416-50b0-e053-d805fe0adaee 9
Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression, file e177fbc7-9e03-50b0-e053-d805fe0adaee 7
Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights, file 9cbeafa1-8654-423e-ab82-f309ae8ac50e 6
Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib, file e177fbc7-a8dd-50b0-e053-d805fe0adaee 6
The role of the microbiome in cancer and therapy efficacy: Focus on lung cancer, file e177fbc7-a994-50b0-e053-d805fe0adaee 6
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios, file e177fbc7-999b-50b0-e053-d805fe0adaee 3
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review, file e177fbc7-ee64-50b0-e053-d805fe0adaee 2
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY, file 474b9f23-6dd8-4880-82b6-2701d9238d1f 1
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients, file e177fbc7-9f9d-50b0-e053-d805fe0adaee 1
Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression, file e177fbc7-a4fa-50b0-e053-d805fe0adaee 1
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study, file e177fbc7-a6a7-50b0-e053-d805fe0adaee 1
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M?, file e177fbc7-a7bd-50b0-e053-d805fe0adaee 1
A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?, file e177fbc7-a8df-50b0-e053-d805fe0adaee 1
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study, file e177fbc7-c993-50b0-e053-d805fe0adaee 1
Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present), file e177fbc7-cfb9-50b0-e053-d805fe0adaee 1
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review, file e177fbc7-ee66-50b0-e053-d805fe0adaee 1
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients, file e177fbc7-f074-50b0-e053-d805fe0adaee 1
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma, file e177fbc7-fc7e-50b0-e053-d805fe0adaee 1
Totale 429
Categoria #
all - tutte 1.265
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.265


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 0 0 0 0 2
2021/2022102 0 0 0 0 1 0 33 3 47 15 2 1
2022/2023218 9 8 3 24 9 10 9 10 81 13 26 16
2023/2024107 4 5 2 2 11 12 43 16 4 8 0 0
Totale 429